In the Specification

Please replace the paragraph beginning on page 48, line 24 with the following amended paragraph:

2

In a first PCR, the repertoire of both conventional (1.6 kb) and heavy-chain (1.3 kb) antibody gene segments were amplified using a leader specific primer (5'-GGCTGAGCTCGGTGGTCCTGGCT-3'; SEQ ID NO: 75) and the oligo d(T) primer (5'-

The resulting DNA fragments were separated by agarose gel electrophoresis and the 1.3 kb fragment encoding heavy-chain antibody segments was purified from the agarose gel. A second PCR was performed using a mixture of FR1 reverse primers (WO03/054016 sequences ABL037 to ABL043) and the same oligo d(T) forward primer.

Please replace the paragraph beginning on page 56, line 6 with the following amended paragraph:

The DNA coding for MP3B4SRA and MP2F6SR VHH was amplified using a FR1 primer (5'-GAGGTBCARCTGCAGGASTCYGG-3'; SEQ ID NO: 77)

and a FR4 primer (5'- GTGTGCGGCCGCTGAGGAGACRGTGACCWG – 3'; SEQ ID NO: 78) introducing a *Pst*1 and a *BstEII* restriction site respectively. The PCR products were purified using a PCR purification kit (Qiagen). Half of the PCR product was digested with *Pst*1 at 37°C for 1 hr and with *BstEII* at 60°C for 1 hr, the other half with *NotI* for 1 hr at 37°C and with *SfiI* for 1 hr at 50°C.

Application No. 10/534,345 Amendment dated June 9, 2008

Preliminary Amendment

Please replace the paragraph beginning on page 56, line 12 with the following amended paragraph:

To construct a bivalent MP3B4SRA/MP3B4SRA, a bivalent MP2F6SR/MP2F6SR and a bispecific MP3B4SRA/MP2F6SR, the PstI/BstEII digested products were purified over gel, ligated into pAX11 (PstI/BstEII) and transformed to WK6 Escherichia coli to obtain clones with a VHH at the C-terminus of the multicloning site. The clones were examined by PCR using the M13 reverse (5'-GGATAACAATTTCACACAGG-3'; SEQ ID NO: 79) and forward (5'-CACGACGTTGTAAAACGAC-3'; SEQ ID NO: 80) primers. From clones yielding a PCR fragment of 650 bp, DNA was prepared and digested with NotI for 1 hr at 37°C and with SfiI for 1 hr at 50°C. Fragments were purified over gel and used as vector to clone the VHH (Sfil/Not1) at the N-terminus of the multicloning site. This yielded a bivalent MP3B4SRA/MP3B4SRA and a bispecific MP3B4SRA/MP2F6SR.

Please replace the paragraphs beginning on page 58, line 12 with the following amended paragraphs:

A functional portion, the CDR3 region of MP2F6SR, was amplified by using a sense primer located in the framework 4 region (F6 CRD3 Forward:CTGGCCCCAGAAGTCATACC; SEQ ID NO: 81) and an anti-sense primer located in the framework 3 region (F6 CDR3 Reverse primer:TGTGCATGTGCAGCAAACC; SEQ ID NO: 82).

In order to fuse the CDR-3 fragment with the anti-serum albumin VHH MSA-21, a second round PCR amplification was performed with following primers:

F6 CDR3 Reverse primer Sfi1:

GTCCTCGCAACTGCGGCCCAGCCGGCCTGTGCATGTGCAGCAAACC (SEQ ID NO: 83) F6 CDR3 Forward primer Not1:

GTCCTCGCAACTGCGCGCCCCCGGCCCCAGAAGTCATACC (SEQ ID NO: 84)